Antimicrobial resistance (AMR) poses an imminent threat to global health security. Pneumococcal vaccination reduces disease incidence, prevents antibiotic use, and decreases antibiotic-resistant infections. However, the benefit of vaccination in reducing AMR has been poorly quantified to date.
The Biden-Harris Administration, working through the Centers for Disease Control and Prevention (CDC), is investing American Rescue Plan funding to strengthen and equip state, local, and territorial public health departments and other partner organizations with the resources needed to better fight infections in U.S. healthcare facilities, including COVID-19 and other known and emerging infectious diseases.
New antifungal agents that are being investigated for possible use against C. auris, such as Ibrexafungerp (Brexafemme), show promise—so far.
As flu season begins, health officials and local vaccinators emphasized getting the influenza vaccine to prevent further strain in already packed hospitals.
With the unpredictability of when it will appear, and its propensity to be multidrug-resistant, this particular pathogen is challenging to diagnose and treat.
CDC has updated select healthcare infection prevention and control (IPC) recommendations in response to COVID-19 vaccination, which are now summarized in this guidance.
CMS, in collaboration with the CDC, is developing an emergency regulation requiring staff vaccinations within the nation’s more than 15,000 Medicare and Medicaid-participating nursing homes.